Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 10/20 | 0.75 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.75 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | GALR3 | O60755 | 1/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14036259 | 1.00 | ADK (0.75) | ADKSLC29A1DOT1LNPC1GALR3 | |
| SCHEMBL14036260 | 1.00 | ADK (0.75) | ADKSLC29A1DOT1LNPC1GALR3 | |
| SCHEMBL20434163 | 1.00 | ADK (0.75) | ADKSLC29A1DOT1LNPC1GALR3 | |
| SCHEMBL10160128 | 1.00 | ADK (0.75) | ADKSLC29A1DOT1LNPC1GALR3 | |
| SCHEMBL314530 | 1.00 | ADK (0.75) | ADKSLC29A1DOT1LNPC1GALR3 | |
| SCHEMBL25352927 | 0.91 | ADK (0.62) | ADKSLC29A1 | |
| SCHEMBL30536337 | 0.91 | ADK (0.62) | ADKSLC29A1 | |
| SCHEMBL23989132 | 0.91 | ADK (0.62) | ADKSLC29A1 | |
| SCHEMBL30536341 | 0.87 | ADK (0.58) | ADKSLC29A1 | |
| SCHEMBL25355187 | 0.87 | ADK (0.58) | ADKSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133080-A1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2017-02-22 | — | — | EP | disclosed |
| EP-2231689-B1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 2016-07-20 | — | — | EP | disclosed |
| US-8093226-B2 | Cytostatic 7-deazapurine nucleosides | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. (CZ) | 2012-01-10 | — | — | US | disclosed |
| US-20090203637-A1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203637-A1 | NOVEL CYTOSTATIC 7-DEAZAPURINE NUCLEOSIDES | TYMP, TYMS, DPYD | ADK 442/4885SLC29A1 15/4885DOT1L 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.